European Primary Care Cardiovascular Society

Diabetes

Diabetes is now considered an important risk factor for cardiovascular disease, and a complex interplay of pathogenic factors complicates management of both diseases.

Consideration of SGLT2 inhibitor treatment in broader T2DM population

3' education - Nov. 26, 2018 - Steve Wiviott, MD - Boston, MA, VS.

CV safety with weight loss agent in high-risk overweight or obese patients

3' education - Aug. 26, 2018 - Dr. Erin Bohula, Boston, MA, US

No overall benefit with aspirin in a primary prevention setting of diabetes patients

3' education - Aug. 27, 2018 - Prof. Jane Armitage, Oxford, UK

Omega-3 fatty acid supplements do not result in CV benefits

3' education - Aug. 26, 2018 - Dr Louise Bowman, Oxford, UK
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (3/3)

Practical management of cardiovascular risk: Lessons from latest diabetes trials

10' education - July 17, 2018 - Prof. Lars Rydén - Stockholm, Sweden
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (2/3)

Diabetes: How to reduce risk from a cardiovascular perspective?

10' education - July 12, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands

The cardiovascular challenge for primary care in diabetes

10' education - July 10, 2018 - Prof. Richard Hobbs - Oxford, UK

Management of CV risk that comes with T2DM in light of novel treatment options

10' education - Mar. 15, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Carlos Brotons, prof. Xavier Cos, prof. Richard Hobbs

Striking results for weight reduction in T2DM in primary care based program

3' education - Dec. 18, 2017 - IDF 2017 - Abu Dhabi, UAE - Prof Naveed Sattar, MD - Glasgow, UK

The evidence base for health behaviour changes

10' education - Dec. 9, 2015 - EPCCS 2015 - Prague, Czech Republic

What's the evidence for BP and lipid targets in diabetes?

3' education - Nov. 25, 2014 - EPCCS 2014, Brussels
##SCROLLER_ITEMS_FULL_TITLE##

Future developments in treating hyperglycemia in type 2 diabetes

3' education - Sep. 20, 2013 - London, 5-6 September 2013 - Neil Munro

Consideration of SGLT2 inhibitor treatment in broader T2DM population

AHA 2018 - Chicago, IL, VS

3' education - Nov. 26, 2018 - Steve Wiviott, MD - Boston, MA, VS.
Dapagliflozin was evaluated in both primary and secondary prevention patients with T2DM. Stephen Wiviott summarizes the results of DECLARE TIMI-58, along with those of a meta-analysis of the 3 SGLT2i CVOTs.

AHA 2018 Dapagliflozin was evaluated in both primary and secondary prevention patients with T2DM. Stephen Wiviott summarizes the results of DECLARE TIMI-58, along with those of a meta-analysis of the 3 SGLT2i CVOTs.

Discovering of more structural brain abnormalities in prediabetes compared to no diabetes

Literature - Nov. 22, 2018 - Van Agtmaal MJM et al. - Diab Care 2018

Structural brain abnormalities are more common in patients with prediabetes compared with non-diabetics, and even more common in T2DM patients.

Lower HF hospitalization with SGLT2 inhibitor in both primary and secondary prevention T2DM patients

AHA 2018 – Chicago, IL, USA

News - Nov. 22, 2018

AHA 2018 Dapagliflozin was associated with a reduction in CVD/hospitalization in T2DM patients with ASCVD or with multiple risk factors, and with a modest decrease in MACE in those with existing ASCVD.

2018 Guidelines on the management of cholesterol: take home messages

News - Nov. 16, 2018

AHA 2018 The American Heart Association (AHA) and the American College of Cardiology (ACC) updated the 2018 cholesterol guidelines. A summary of key recommendations concerning cholesterol management in de prevention of CVD.

Intensive lifestyle intervention program associated with reduced CV risk in overweight/obese adults

Literature - Nov. 9, 2018 - Salas-Salvadó J et al. - Diabetes Care 2018

In this randomized trial, the long-term intensive PREDIMED-Plus lifestyle intervention resulted in weight loss and reduced CV risk in overweight/obese adults with metabolic syndrome, compared to standard care.

Improving glycemic control can reduce CV outcomes, possibly via BP regulation

Literature - Oct. 25, 2018 - Schwarz PEH et al. - J Am Coll Cardiol 2018

This umbrella review of recent systematic reviews and meta-analyses compared the effectiveness and underlying mechanisms of various prevention and treatment strategies to regulate blood glucose.

Association between GLP-1 receptor agonist therapy and decreased CV risk in T2DM patients with CKD

Literature - Oct. 18, 2018 - Mann JFE et al. - Circulation 2018

In a posthoc analysis of the LEADER trial, liraglutide treatment was associated with fewer CV outcomes in patients with type 2 diabetes and chronic kidney disease at high CV risk.

New EASD-ADA consensus guidelines on managing hyperglycemia in T2DM

News - Oct. 9, 2018

EASD 2018 Following a review of the latest evidence, the EASD and the ADA introduced new recommendations on managing hyperglycemia in T2DM, including specific drug classes for some patients and enhancing medication adherence.

Diabetes may begin more than 20 years before diagnosis

News - Oct. 9, 2018

EASD 2018 Increased fasting glucose, higher BMI and impaired insulin sensitivity were detectable up to 10 years before the diagnosis of diabetes as well as prediabetes.

Importance increasing BMI from age 10 to adulthood in development T2DM

News - Oct. 3, 2018

EASD 2018 Weight gain between the age of 10 and adulthood is associated with T2DM risk. Overweight children at age 10 appear to be at lower risk for developing T2DM than children who are regular weight at age 10 and then later become overweight as adults.

How quickly T2DM progresses is determined by multiple factors

News - Oct. 3, 2018

EASD 2018 A study found various clinical and biochemical factors that are associated with a greater risk of fast disease progression in T2DM patients.

CV safety with weight loss agent in high-risk overweight or obese patients

3' education - Aug. 26, 2018 - Dr. Erin Bohula, Boston, MA, US
In overweight or obese patients with CVD or diabetes with one CV risk factor, lorcaserin demonstrated to be safe with respect to CV outcomes. Dr. Bohula discussed the implications of the CAMELLIA-TIMI 61 trial.

ESC 2018 In overweight or obese patients with CVD or diabetes with one CV risk factor, lorcaserin demonstrated to be safe with respect to CV outcomes. Dr. Bohula discussed the implications of the CAMELLIA-TIMI 61 trial.